RapidArc Radiotherapy Technology Enabling Fast, Accurate Treatments For Pennsylvania Cancer Patients

RapidArc Radiotherapy Technology Enabling Fast, Accurate Treatments For Pennsylvania Cancer Patients
Two patients, both in their 70s, have become the first people in Allentown, Pennsylvania, to receive a new, faster, more precise form of radiotherapy for cancer. A 72-year-old man was treated for prostate cancer, while a 70-year-old woman received treatment for a brain tumor at the base of her skull.

Circassia's Allergy Therapy Begins Phase II Clinical Trial In Asthma Patients

Circassia's Allergy Therapy Begins Phase II Clinical Trial In Asthma Patients
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced that it has initiated a phase II clinical study of its ToleroMune(R) technology in allergy patients with asthma. The trial builds on positive phase II results that demonstrated the potential clinical benefits of ToleroMune allergy therapy, and extends clinical investigations to those with allergy-associated asthma.

Biomerica Receives CE Mark Approval For 5-Minute Home Test For Kidney Disease Screening For Diabetic And Hypertensive Individuals

Biomerica Receives CE Mark Approval For 5-Minute Home Test For Kidney Disease Screening For Diabetic And Hypertensive Individuals
Biomerica, Inc. (OTCBB: BMRA) announced that it has received approval to CE mark its 5-minute home diagnostic test for detecting Microalbumin, micro amounts of albumin in urine. Albumin is normally found in the blood and filtered by the kidneys. When the kidneys are working properly, albumin is not present in urine in significant amounts. However, when the kidneys are damaged, small amounts of albumin leak into the urine, resulting in elevated levels.